* Patients with severe hepatic impairment (Child-Pugh A/B/C)
* Uncontrolled diabetes mellitus
* Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of study drugs (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome)
Patients who test positive for hepatitis B or C
Patients being treated with drugs recognized as being strong inhibitors or inducers of the isoenzyme CYP3A within the last 5 days prior to enrollment
History of non-compliance to medical regimens
Patients unwilling to or unable to comply with the protocol
Clareo Health | Influence of Exceptional Patient Characteristics on Everolimus Exposure
